A change of in vivo characteristics depending on specific activity of radioiodinated (+)-2-[4-(4-iodophenyl)piperidino]cyclohexanol [(+)-pIV] as a ligand for sigma receptor imaging

Nuclear Medicine and Biology

Volumn 35, Issue 1, 2008, Pages 29-34

  Akhter, Nasima ^a   Shiba, Kazuhiro ^a   Ogawa, Kazuma ^a   Tsuji, Shiro ^a   Kinuya, Seigo ^a   Nakajima, Kenichi ^a   Mori, Hirofumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

(+) p Iodovesamicol; Biodistribution; High and low specific activity radiolabeled (+) pIV; Radioligand; Sigma 1 receptor

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 2 [4 (4 IODOPHENYL)PIPERIDINO]CYCLOHEXANOL; 4 IODOVESAMICOL; HALOPERIDOL; PENTAZOCINE; RADIOACTIVE IODINE; UNCLASSIFIED DRUG; VESAMICOL;

ARTICLE; BLOOD CELL; BRAIN REGION; IN VIVO STUDY;

ANIMALS; AUTORADIOGRAPHY; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANOLS; IODINE RADIOISOTOPES; MALE; PIPERAZINES; PIPERIDINES; PROTEIN BINDING; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA; TISSUE DISTRIBUTION;

EID: 37349102472     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.09.005     Document Type: Article

References (29)

1. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilber P.E. The effects of morphine and morphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197 (1976) 517-532
2. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., de Costa B., and Rice K.C. Sigma receptors: biology and function. Pharmacol Rev 42 (1990) 355-402
3. Quirion R., Bowen W.D., Itzhak Y., Junien J.L., Musacchio J.M., Rothman R., et al. A proposal for the classification of σ-binding sites. Trends Pharmacol Sci 13 (1992) 85-86
4. Weissman A.D., Su T.-P., Hedreen J.C., and London E.D. Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther 247 (1988) 29-33
5. Su T.-P. Delineating biochemical and functional properties of sigma receptors: emerging concepts. Crit Rev Neurobiol 7 (1993) 187-203
6. Maurice T., Hiramatsu M., Itoh J., Kameyama T., Hasegawa T., and Nabeshima T. Behavioral evidence for a modulating role of sigma ligands in memory processes: I. Attenuation of dizocilpine (MK-801)-induced amnesia. Brain Res 647 (1994) 44-56
7. Jansen K.L., Faull R.L., Storey P., and Leslie R.A. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. Brain Res 623 (1993) 299-302
8. Helmeste D.M., Tang S.W., Bunney Jr. W.E., Potkin S.G., and Jones E.G. Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains. Eur J Pharmacol 314 3 (1996) R3-R5
9. Simpson M.D.C., Slater P., Royston M.C., and Deakin J.F.W. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res 6 (1992) 41-48
10. Weissman E.D., Casanova M.F., Kleinman J.E., London E.D., and De Souza E.B. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 29 (1991) 41-54
11. Collier T.L., Waterhouse R.N., and Kassiou M. Imaging sigma receptors: applications in drug development. Curr Pharm Des 13 1 (2007) 51-72
12. John C.S., Bowen W.D., Saga T., Kinuya S., Vilner B.J., et al. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)-4-iodobenzamide. J Nucl Med 34 (1993) 2169-2175
13. Choi S.R., Yang B., Plossl K., Chumpradit S., Wey S., Acton P.D., et al. Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. Nucl Med Biol 28 (2001) 657-666
14. 123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]piperidine. J Med Chem 40 (1997) 1657-1667
15. 123I]1-(4-cyanobenzyl)-4-[(trans-iodopropen-2-yl)oxymethyl]piperidine: a novel high affinity sigma receptor radioligand for SPECT. Nucl Med Biol 24 (1997) 45-51
16. 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents: initial studies in mouse tumor models. Nucl Med Biol 24 (1997) 587-593
17. 18F]-1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: a potential sigma-a receptor radioligand for PET. J Label Compd Radiopharm 38 (1996) 785-794
18. 18F]-1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: a selective sigma-1 receptor radioligand for PET. Nucl Med Biol 24 (1997) 127-134
19. 18F] labeled benzamides: high affinity sigma receptor ligands for PET imaging. Nucl Med Biol 24 (1997) 333-340
20. 18F]fluoro-benzamide: a potential ligand for PET imaging of σ receptors. Nucl Med Biol 24 (1997) 671-676
21. 11C]NE-100 labeled in two different positions as a PET σ receptor ligand. Nucl Med Biol 2 (1998) 195-202
22. 11C]SA4503: radiation dosimetry, in vivo selectivity and PET imaging of sigma-1 receptors in the cat brain. Ann Nucl Med 14 (2000) 285-292
23. 11C]methoxy-1,2,3,4-tetrahydrochromeno[3,4-c]pyridine-5-one: a PET tracer for imaging sigma-1 receptors. Nucl Med Biol 29 (2002) 469-476
24. Shiba K., Ogawa K., and Mori H. Characterization of radioiodinated (+)-2-[4-(4-iodophenyl)piperidino]cyclohexanol [(+)-pIV] as a sigma receptor ligand. Bioorg Med Chem 13 4 (2005) 1095-1099
25. Akhter N., Shiba K., Ogawa K., Kinuya S., Nakajima K., and Mori H. In vivo characterization of radioiodinated (+)-2-[4-(4-iodophenyl)piperidino]cyclohexanol [(+)-pIV] as a potential sigma-1 receptor imaging agent. Nucl Med Biol (2007) [in press]
26. 11C]SA4503. Nucl Med Biol 30 (2006) 543-548
27. McLean S., and Weber E. Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea brain. Neuroscience 25 (1988) 259-269
28. 3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J Neuroscience 6 6 (1986) 1757-1770
29. 11C]diprenorphine and positron emission tomography. J Cereb Blood Flow Metab 11 2 (1991) 204-219